In subsequent clinical trials, the team used [11C]UCB -J to perform PET imaging of SV2A to further confirm that there is a decrease in synaptic density in the medial temporal area and neocortical brain area of early AD patients (Mecca et al., 2020). This evidence concerns the gene SV2A and Alzheimer disease.